Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

By V. Heinemann, D. Quietzsch, F. Gieseler, M. Gonnermann, H. Schönekäs, A. Rost, H. Neuhaus, C. Haag, M. Clemens, B. Heinrich and 10 more. Journal of Clinical Oncology, 2006

687 citations recorded by the source corpus.

Subfields: Epidemiology, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/efbfc2b7dc8831583ebba9ec942ec4898078b1a5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

Citations in the corpus

Stromal biology and therapy in pancreatic cancer (2010, background): “To this end, large randomised phase III trials were performed to evaluate additional effects of cisplatin,”
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. (2021, background): “Of note, results from several studies have indicated that the benefit of gemcitabine combination chemotherapy is predominantly seen in patients with good performance status.(149,150,152)”
Recent progress in pancreatic cancer (2013, result): “Gemcitabine plus oxaliplatin or gemcitabine in combination with cisplatin showed no statistically significant improvement in survival in phase 3 trials, although the results may have trended in that direction.(165,196,197) Selected subgroups of patients may, however, benefit.”
Advanced pancreatic carcinoma: current treatment and future challenges (2010, background): “Large randomized phase III trials were performed to evaluate the combination of gemcitabine with cisplatin”
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). (2010, background): “Negative phase III results despite promising single-arm phase II data are, unfortunately, a common outcome in pancreatic cancer trials.(3-10) These collective data suggest that in this disease, a single-arm, phase II trial design may not be not optimal.”